JPRN-jRCT2080221239未知2 期
Phase 2 Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response
Bristol-Myers K.K.0 个研究点目标入组 56 人开始时间: 2010年9月10日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Subjects must have recurrent, metastatic or progressive NSCLC
- •Pathologically confirmed NSCLC
- •Previously received treatment with single agent Gefitinib or Erlotinib
- •Any one of the following:
- •- A tumor that harbors an EGFR mutation
- •- Objective clinical benefit from treatment with Gefitinib or Erlotinib
- •- Progression of NSCLC while on continuous treatment with gefitinib or erlotinib as noted by CT/MRI increase in disease within 3 months of study enrollment
排除标准
- •- Symptomatic brain metastasis
- •- Adequate organ function and performance status
研究者
相似试验
已完成
2 期
Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior ResponseNon-Small-Cell Lung CarcinomaNCT01167244Bristol-Myers Squibb11
进行中（未招募）
1 期
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2018-000416-21-FIBristol-Myers Squibb International Corporation435
进行中（未招募）
1 期
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000416-21-PLBristol-Myers Squibb International Corporation435
进行中（未招募）
1 期
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 20.0Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2018-000416-21-ESBristol-Myers Squibb International Corporation300
进行中（未招募）
1 期
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and inCombination with Nivolumab in Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2018-000416-21-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO450